Azilsartan Trimethylethanolamine Due Diligence Report 2026

This Azilsartan Trimethylethanolamine Drug Asset Due Diligence Report was built with PatSnap Life Sciences MCP workflows. Drug & Asset MCP establishes identity, ownership and stage; Clinical Trials MCP checks design, endpoints and readouts; Company & Deal Intelligence MCP reconstructs transaction precedent. Explore the MCP servers used in this report.

Decision date: 16 September 2026. Currency fields are presented in US$ millions as returned by the deal dataset. This is a screening memorandum, not legal, medical, patent or investment advice.

Phase 2

Highest phase

Registered trials

Result records

Matched deals

Executive recommendation: HOLD / OPTION

Decision memo

Preserve optionality until clinical differentiation, transaction economics, and freedom-to-operate are sufficiently de-risked.

The central underwriting question is whether Azilsartan Trimethylethanolamine can convert its Small molecule drug profile and AT1R biology into clinically meaningful differentiation while preserving an investable safety, IP and commercial position.

1. Asset identity and development status

Asset	Azilsartan Trimethylethanolamine (query alias: Azilsartan Trimethylethanolamine)
Modality / target	Small molecule drug; AT1R; AT1R antagonists
Highest global status	Phase 2
Originator	Jiangsu Hansoh Pharmaceutical Group Co., Ltd.
Active developers	Jiangsu Hansoh Pharmaceutical Group Co., Ltd.

The MCP disease footprint includes Essential Hypertension. The highest-phase flag is a useful orientation point, but the licensing case depends on indication-level evidence and rights, not the global label alone.

2. Clinical program: design and endpoint audit

Registry	Phase	Status	Enrollment	Lead primary endpoint
CTR20150603	Phase 2	Recruiting	225	Primary endpoint not disclosed in English source
CTR20150525	Phase 1	Completed	12	Primary endpoint not disclosed in English source
ChiCTR-OOC-15006740	Not Applicable	Recruiting	14	Primary endpoint not disclosed in English source

The trial set should be diligenced for randomization, comparator relevance, endpoint hierarchy, analysis population, multiplicity, geographic mix and readout timing. For early-stage studies, safety and dose selection can be as decision-critical as response rate.

Reproduce the asset-to-trial workflow with PatSnap MCP

3. Clinical readouts: what is known

Evidence gap

The Clinical Trials MCP returned no matched public result record. This is a gating diligence gap, not evidence of failure.

These fields are structured evidence signals, not a substitute for statistical review. The next diligence pass should reconcile denominators, confidence intervals, follow-up, censoring, dose cohorts and treatment-emergent toxicity against the original abstract, registry and protocol.

4. Market and competitive position

Azilsartan Trimethylethanolamine addresses Essential Hypertension. Commercial attractiveness rests on addressable patients, treatment-line placement, duration, administration burden, pricing and displacement of entrenched standards. The modality—Small molecule drug—must demonstrate a benefit large enough to offset class-specific safety and operational costs.

The MCP screen returned 44 matched transaction record(s) under the scope “target-level comparable: AT1R.” Partner activity is a market-validation signal, but it does not establish net present value.

5. Transaction precedent and economics

Transaction-scope note: No direct asset-specific transaction was returned. The table below shows target-level comparable: AT1R records as comparable precedents only.

Date	Transaction	Phase at deal	Disclosed economics
2026-06-16	Everest Medicines Enters into Exclusive Licensing Agreement with Dimerix for DMX-200 in Greater China, South Korea and Southeast Asia	Phase 3	US$10.0M upfront; US$330.0M milestones
2026-03-16	George Medicines extends global commercialization of GMRx2 into Australia and New Zealand with Arrotex licensing agreement	Phase 3	Financial terms not disclosed
2026-03-11	George Medicines signs exclusive licensing agreement with Ahngook Pharmaceutical to commercialize GMRx2 in Korea	Phase 3	Financial terms not disclosed

Headline values are not directly comparable. Diligence should normalize upfront cash, equity, development and sales milestones, tiered royalties, opt-in mechanics, cost sharing, change-of-control clauses and geography.

6. IP and freedom-to-operate screen

The milestone feed surfaced a patent-application signal described as “Method for detecting genotoxic impurities in antihypertensive drug intermediates”. The milestone feed surfaced a patent-application signal described as “Preparation process of azilsartan micro-powder raw material drug”. The milestone feed surfaced a patent-application signal described as “High-purity, small-particle-diameter and low-solvent-residue azilsartan bulk drug and preparation method thereof”.

The claim chart should separately test composition or sequence coverage, formulation and dosing, indication and biomarker claims, combinations, manufacturing know-how, prosecution history, term extensions and third-party blocking rights.

7. Principal risks and diligence gates

Therapeutic index and off-target toxicity
Resistance biology and biomarker-defined patient selection
Differentiation from established and emerging standards

Cross-functional diligence should also test CMC comparability, supply chain, pharmacovigilance, regulatory correspondence, data integrity, investigator concentration, partner obligations and change-of-control restrictions.

8. Final go/no-go memorandum

HOLD / OPTION